The road to cannabis rescheduling was never going to be a straight line, and this week proved it. Just days before the Drug Enforcement Administration is set to open its long-awaited hearing on moving marijuana to Schedule III, a coalition of opponents went to court to try to stop the whole thing in its tracks. For anyone who has followed federal cannabis policy through a decade of false starts, the move is both unsurprising and a useful reminder: reform doesn't happen because the momentum is obvious. It happens over the objections of people fighting hard to prevent it.
Here is what actually happened. Three parties — the National Drug and Alcohol Screening Association, the anti-legalization group Smart Approaches to Marijuana (SAM), and a pharmaceutical developer called MMJ International Holdings — petitioned the U.S. Court of Appeals for the D.C. Circuit to stay the Trump administration's April order rescheduling state-licensed cannabis from Schedule I to Schedule III. Their core argument is procedural: that the order bypassed the scientific review and public-comment process the law requires. The DEA's broader administrative hearing on rescheduling is still scheduled to begin June 29, with selected participants notified on June 22. The petitioners want the court to halt the proceedings before they open.
Why opponents are going to court now
Timing is everything in litigation, and the timing here is deliberate. Once an administrative hearing begins and builds a formal record, it becomes much harder to unwind. By seeking a stay before June 29, opponents are trying to freeze the process at the last possible moment when a single court order could still stop it cleanly. It's a familiar legal playbook: when you can't win the argument on the merits, you try to win on procedure and delay.
The choice of plaintiffs tells its own story. A drug-testing trade association has an obvious commercial interest in cannabis remaining tightly restricted — looser classification can erode the demand for workplace testing. SAM has spent years as the most organized voice against legalization. And a pharmaceutical developer brings the argument that cannabis should move through the FDA drug-approval pipeline rather than a state-licensed market. Each comes at it from a different angle, but the shared goal is the same: keep the existing framework in place.
When reform opponents can't stop a policy on substance, they reach for procedure. A stay isn't a victory — it's an attempt to run out the clock.
What a stay would — and wouldn't — do
Let me be precise, because the stakes get exaggerated in both directions. If the D.C. Circuit grants the stay, it would pause the rescheduling process, potentially delaying the June 29 hearing and everything downstream of it. That would be a real setback for an industry that has waited years for federal movement. But a stay is not a final ruling. It freezes the status quo while the court considers the underlying challenge; it doesn't permanently kill rescheduling.
If the court denies the stay — which rescheduling supporters expect — the hearing proceeds on schedule, and the procedural challenge continues in the background without stopping the clock. Either way, this is almost certainly not the last courtroom fight. Major regulatory shifts of this magnitude routinely draw litigation from every direction, and rescheduling will be no exception. The smart way to read this petition is as the opening move in a longer legal contest, not a decisive blow.
What it means for New York
For operators and shoppers in New York, the immediate practical impact is essentially zero. Rescheduling is a federal matter that affects taxation, research access, and the medical channel — it plays out over months and quarters, not at the dispensary counter. Legal sales here continue exactly as they did yesterday. No store closes, no price changes, no product disappears because of a court filing in Washington.
What's worth watching is the medium term. The biggest prize of rescheduling for the broader industry is relief from the punishing 280E tax burden and a friendlier posture toward banking and capital. A delay pushes those benefits further out, which matters most to operators trying to plan investment and expansion. New York's market has been one of the country's fastest-growing, and a cleaner federal backdrop would give operators here more room to compete — which, over time, tends to show up as sharper pricing and better selection for consumers. You can already see how competitive the market has become by comparing the day's cannabis deals across licensed New York dispensaries on High Today.
What to watch next
Three dates frame the next two weeks. June 22, when the DEA is expected to notify the participants selected for the hearing. June 29, when the hearing is scheduled to open — assuming no stay is granted. And, hanging over both, whatever the D.C. Circuit decides on the stay request in the interim. A denial keeps the process moving and signals the courts aren't inclined to second-guess the order on procedural grounds. A grant would hand opponents a meaningful delay and inject fresh uncertainty into a market that has had more than enough of it.
I've learned not to celebrate cannabis reform until the ink is dry, and not to panic at every legal challenge either. This petition is exactly the kind of friction you should expect when a decades-old prohibition framework finally starts to crack. The opponents are organized, well-funded, and motivated — but they're now fighting a rear-guard action against a process the federal government itself set in motion. That's a very different position than they occupied even two years ago. The fight isn't over. It rarely is. But the direction of travel is harder to reverse than a single court filing suggests. For adults 21+.